A multi-institutional clinical trial of proton beam therapy for localized intermediate-risk prostate cancer

A multi-institutional clinical trial of proton beam therapy for localized intermediate-risk prostate cancer - A multi-institutional clinical trial of proton beam therapy for localized intermediate-risk prostate cancer

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000025453

Enrollment

200

Registered

2017-03-01

Start date

2017-12-26

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

localized intermediate-risk prostate cancer

Interventions

Proton beam radiation therapy (63 GyE)

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: Pathology: Adenocarcinoma No LN/distant metastasis KPS: 70 or more and estimated 5-year survival Androgen deprivation therapy: 6-8 months A written informed consent

Exclusion criteria

Exclusion criteria: Previous prostate cancer treatment: surgery, HIFU, chemotherapy, and others Other cancers within 5 years History of radiation therapy for pelvis Uncontrolled infection or DM more than 135 Kg

Design outcomes

Primary

Measure	Time frame
5-year biochemical relapse-free survival rate	—

Countries

Japan

Contacts

Public ContactHitoshi Ishikawa

University of Tsukuba, Faculty of Medicine Proton Medical Research Center

hishikawa@pmrc.tsukuba.ac.jp0298537100

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026